Camurus and Eli Lilly enters into a collaboration and licensing agreement regarding long-acting incretins based on FluidCrystal. Read more.
Biomarker data from Alligator Biosciences OPTIMIZE-1 clinical trial presented at the ASCO 2025 Annual Meeting. Read more.
Iconovo announces the final outcome of the rights issue. Read more.
OncoZenge announces that LINK Medical has been hired to conduct a feasibility study in Europe, for the company's planned Phase III study for European approval of BupiZenge. Read more.
UsDsign is investigating the conditions for implementing a directed new issue of approximately nine million shares through an accelerated bookbuilding process aimed at Swedish and international institutional investors, which will be initiated immediately. Read moreOssDsign then investigated the possibilities of increasing the scope of the directed new share issue to approximately 11,5 shares. Read moreFinally, OssDsign has completed a directed new share issue of approximately SEK 158 million. Read more.
Prostatype Genomics announces that strong results from a study in Taiwan with the company's prognostic genetic test Prostatype have now been published in the scientific journal BJUI Compass. Read more.
SynAct Pharma is taking out a credit facility of SEK 30 million that extends the company's financial runway until mid-2026 and at the same time strengthens partnership opportunities. Read more.
Nanexa highlights NEX-22 and PharmaShell in an intensive international exposure period. Read more.
SyntheticMR announces that a new multicenter study demonstrates SyMRI's potential to transform clinical workflows in neuroimaging. Read more.
Curasight informs that the subscription period for warrants of series TO3 begins on June 4, 2025. Read more.
Moberg Pharma The Board of Directors utilizes issuance and repurchase authorizations and converts Series C shares into common shares to secure the company's commitments under incentive programs and for the purpose of covering certain expenses that may arise in connection with incentive programs. Read more.
Fleries portfolio company KAHR Cinema presents positive results from a phase II clinical trial with DSP107 in combination with anti-PD-L1 in colorectal cancer. Read moreFlerie has also provided information about net asset value. Read more.
Implantica announces that the British NICE has published positive recommendations for the RefluxStop procedure in NHS public hospitals. Read more.
Nexstim receives order for NBS System 5 from children's hospital in the USA. Read more.
Oblique Therapeutics is carrying out an issue of convertibles of approximately SEK 15,2 million, primarily directed at existing shareholders. Read more.
Orion announces that the FDA approves the third indication for darolutamide for patients with advanced prostate cancer. Read more.
BergenBio provides an update on the business. Read more.
Subscription period for Diagonal Cinemas Series TO 2 warrants begin today. Read more.
Insider trading & whistleblowing
ArcticZymes Technologies Faron Pharmaceuticals oculis Vistin Pharma
Invitations & presentations
AlzeCure Pharma BioInvent International Coloplast IRLAB Therapeutics iZafe Group oculis sobi
